US 9580438
Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders
granted A61PA61P25/00A61P25/20
Quick answer
US patent 9580438 (Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders) held by 4SC DISCOVERY GMBH expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- 4SC DISCOVERY GMBH
- Grant date
- Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61P, A61P25/00, A61P25/20, A61P29/00, A61P35/00